NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-275-2002-1-PCT-01 Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy PCT PCT COMB PCT/US2003/027873 Expired
NCI E-082-2004-2-US-02 Methods Of Preventing Or Treating T Cell Malignancies By Adminstering CD2 Antagonists US ORD 10/657,006 Abandoned
NCI E-035-2002-0-EP-06 Backbone-Substituted Bifunctional DOTA Ligands, Complexes and Compositions Thereof, and Methods of Using Same EP National Stage 03752034.3 Abandoned
NCI E-082-2004-2-EP-03 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists EP National Stage 03755798.0 Abandoned
NCI E-082-2004-2-EP-09 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists EP DIV 3755798 Abandoned
NCI E-082-2004-2-CN-04 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists CN National Stage 03824932.4 Abandoned
NCI E-082-2004-2-CA-07 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists CA National Stage 2497628 Abandoned
NCI E-245-2002-0-DE-08 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF DE EP 03751981.6 Abandoned
NCI E-245-2002-0-FR-09 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF FR EP 03751981.6 Abandoned
NCI E-245-2002-0-GB-10 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF GB EP 03751981.6 Abandoned
NCI E-245-2002-0-EP-07 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF EP National Stage 03751981.6 Abandoned
NCI E-245-2002-0-CA-05 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF CA National Stage 2497572 Abandoned
NCI E-245-2002-0-AU-04 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF AU National Stage 2003270087 Abandoned
NCI E-245-2002-0-PCT-02 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PCT PCT PCT/US2003/027607 Expired
NCI E-234-2003-0-US-01 Methods For Identifying, Diagnosing, And Predicting Survival of Lymphomas US 60/500,377 Abandoned
NEI E-304-2003-0-PCT-02 Venting and Drying of Samples in Multi-Well Plates PCT PCT PCT/US03/27400 Abandoned
CC E-145-1998-0-US-04 Identification of a Region of the Major Surface Glycoprotein (MSG) Gene of Human Pneumocystis Carinii US DIV 10/654,416 Abandoned
NEI E-304-2003-0-EP-05 Venting and Drying of Smaples in Multi-Well Plates EP National Stage 03749312.9 Abandoned
NEI E-304-2003-0-AU-04 Venting and Drying of Samples in Multi-Well Plates AU National Stage 2003268352 Abandoned
NCI E-323-2003-0-US-01 Minimally Immunogenic Variants of SDR-Grafted Humanized Antibody CC49 and Their Use US 60/498,903 Abandoned
NCI E-282-2000-0-JP-05 Analogs of Thalidomide as Potential Angiogenesis Inhibitors JP National Stage 2002-567927 Abandoned
NIDA E-024-2005-0-US-01 Pyridomorphinans, Pyridazinomorphinans And Use Thereof US 60/497,901 Abandoned
NHLBI E-179-2004-0-US-01 Anti-cancer Vaccines US 60/498,238 Abandoned
NICHD E-225-1997-8-US-01 Methods And Compositions For The Treatment Of Fribrotic Conditions & Impaired Lung Function & To Enchance Lyphocyte Production US CIP 10/647,371 Abandoned
NIAID E-286-2002-1-US-01 The Use Of Aerosolized Capreomycin For The Treatment Of Pulmonary Tuberculosis US 60/497,892 Abandoned
NICHD E-147-1996-5-HK-10 Use of ADNF-For Enhancing Learning and Memory HK EP 03106025.3 Abandoned
NIAID E-115-2001-3-US-02 MVA Expressing Modified HIV Envelope, GAG and POL Genes US ORD 10/646,628 Abandoned
NINDS E-167-2004-0-US-01 Inducing Sterility In Fish By Disrupting The Development Of The GNRH System US 60/497,401 Abandoned
NCI E-187-2000-0-HK-08 A Recombinant Non-Replicating Virus Expressing GM-CSF and Uses Thereof to Enhance Immune Responses HK National Stage 03105975.5 Abandoned
NIAID E-001-2004-0-US-01 Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein US 60/496,660 Abandoned
NIDCR E-015-2002-1-US-03 Mammalian Sweet Taste Receptors US CON 10/645,441 7507793 Expired PDF
NCI E-009-2000-0-HK-24 Anti-EGFRvIII scFvs With Improved Cytotoxicity and Yield, Immunotoxin Based Thereon, and Methods of Use Thereof HK National Stage 03105948.9 Abandoned
NCI E-148-1998-1-US-04 Molecular Clones With Mutated HIV GAG/POL,SIV GAG And SIV ENV Genes US DIV 10/644,027 7608422 Abandoned PDF
NCI E-304-2000-1-PCT-01 ABCA13 Nucleic Acids And Proteins, And Uses Thereof PCT PCT COMB PCT/US03/26335 Abandoned
NCI E-173-2001-0-PCT-02 HTLV-1 p30II AND p12 PROTEINS AS THERAPEUTIC TARGETS IN HTLV-1 INFECTED INDIVIDUALS PCT PCT PCT/US03/25958 Abandoned
NCI E-342-2003-0-PCT-02 Hepatitis C Viral-Like Particle Purification PCT PCT PCT/US2003/025674 Expired
NCI E-342-2003-0-EP-04 Hepatitis C Viral-Like Particle Purification EP National Stage 03788563.9 Abandoned
NCI E-342-2003-0-CA-05 Hepatitis C Viral-Like Particle Purification CA National Stage 2495680 Abandoned
NCI E-342-2003-0-AU-06 Hepatitis C Viral-Like Particle Purification AU National Stage 2003265454 Abandoned
NIEHS E-170-2000-0-US-03 Non-Steroidal Anti-Inflammatory Drug Related Gene With Anti-Tumorigenic Properties US National Stage 10/363,514 7141661 Expired PDF
NCI E-190-2000-0-US-06 Methods and Compositions For Inhibiting HIV-Coreceptor Interactions US National Stage 10/468,182 Abandoned
NHLBI E-304-2002-2-US-01 Countercurrent Chromatography Separation Of Polar Sulfonated Compounds US CIP 10/641,805 Abandoned
NEI E-220-2001-0-US-10 Nutritional Supplement to Treat Macular Degeneration US CON 10/641,668 Abandoned
CC E-248-2001-0-PCT-02 Apparatus for Multifocal Deposition and Analysis and Methods for Its Use PCT PCT PCT/US03/25575 Abandoned
NINDS E-056-2003-0-US-01 Methods for the Differentiation of Human Embryonic Stem (ES) Cells into Neuronal Cells US 60/495,346 Abandoned
NICHD E-225-1997-1-US-02 USE OF RECOMBINANT HUMAN UTEROGLOBIN IN TREATMENT OF INFLAMMATORY AND FIBROTIC CONDITIONS US CON 10/638,448 Abandoned
NIAID E-017-1996-1-US-04 CELLS EXPRESSING BOTH HUMAN CD4 AND A HUMAN FUSION ACCESSORY FACTOR ASSOCIATED WITH HIV INFECTION US DIV 10/638,797 Abandoned
NIAID E-088-2000-0-US-06 Compositions and Method For Preventing Reactogenicity Associated With Administration Of Immunogenic Live Rotavirus Compositions US National Stage 10/181,908 7431931 Expired PDF
NIDCR E-268-2002-0-US-02 RECOMBINANT MODIFIED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN FOR USE IN VACCINES US ORD 10/638,006 7261900 Expired PDF
NCI E-292-2003-0-US-01 Gene Expressed In Breast Cancer And Method of Use US 60/493,522 Abandoned